FIRST AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • June 5th, 2024 • Coya Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Development and License Agreement (this “First Amendment”) is made and entered into effective as of June 4, 2024 (the “First Amendment Effective Date”) by and between Coya Therapeutics, Inc., a Delaware corporation having its registered office at 5850 San Felipe St., Suite 500, Houston, Texas 77057, USA (“Coya”) and Dr. Reddy’s Laboratories SA, a Swiss company having its place of business at Elisabethenanlage 11, CH—4051, Basel, Switzerland (“DRL”). Capitalized terms used but not defined in this First Amendment shall have meanings ascribed to such terms in the Agreement (as defined below).
